CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up
The PD-1 antibody nivolumab produced responses in about seven in ten patients whose Hodgkin lymphoma had returned after a stem cell transplant, with responses lasting well over a year, confirming the exquisite sensitivity of this lymphoma to checkpoint blockade.
Overview
Multicohort single-arm phase 2 study of 243 patients with classical Hodgkin lymphoma relapsed or refractory after autologous stem cell transplantation, treated with nivolumab; cohorts were brentuximab-naive, brentuximab after transplant, and brentuximab before and/or after transplant.
With extended follow-up the objective response rate was 69 percent, median duration of response 16.6 months and median progression-free survival 14.7 months; responses were independent of PD-L1 expression level, and the safety profile matched other nivolumab studies. The data underpinned regulatory approval of nivolumab in this setting.
- Objective response 69 percent; median duration of response 16.6 months; median progression-free survival 14.7 months.
Nivolumab, like pembrolizumab, is a standard for relapsed Hodgkin lymphoma after transplant, and the activity seen here led to its testing in first-line therapy (S1826).
- Single-arm; no randomised comparison with brentuximab vedotin.
- Complete responses were a minority and most patients eventually progressed.
Similar pages
not linked directly; found by shared links- PairingPD-1 blockade + AVD chemotherapy
Shares CheckMate 205, Nivolumab.
- Key paperNivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis
Shares Journal of Clinical Oncology, Nivolumab.
- Key paperDREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma
Shares Journal of Clinical Oncology, Nivolumab.
- Key paperLow-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)
Shares Journal of Clinical Oncology, Nivolumab.
- Key paperASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors
Shares Journal of Clinical Oncology, Nivolumab.
- CancerEarly-stage classical Hodgkin lymphoma (stage I to II)
Shares Relapsed and refractory classical Hodgkin lymphoma, Nivolumab.